Facioscapulohumeral Muscular Dystrophy (FSHD)

all catalysts(0)

nothing on the calendar yet

News(8)

• Roche drops muscle-sparing obesity antibody after flunked interim analysis
  Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.
  fiercebiotech · 5d ago
• After Novartis’ devastating M&A losses, long live the executive willing to try
  Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular dystrophy and ALS hit major roadblocks this month.
  biospace · 16d ago
• Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
  The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Bioscien…
  fiercebiotech · 25d ago
• Epicrispr, Infinimmune snag combined $165M in VC cash
  Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
  biospace · 1mo ago
• Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
  The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
  biopharma_dive · 1mo ago
• Epicrispr raises $90M to rewrite treatment of rare muscle disease
  Epicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medicines led by an e…
  fiercebiotech · 1mo ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 1mo ago
• Novartis RNA drug acquired in $12B Avidity deal notches a trial win
  The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
  biopharma_dive · 3mo ago